



## ADULT CKD - EPOETIN/IRON ORDERS

AUTHORIZATION IS GRANTED TO DISPENSE AND ADMINISTER AN ALTERNATE DRUG PRODUCT ACCEPTABLE TO THE MEDICAL STAFF'S PHARMACY COMMITTEE UNLESS THE DRUG PRODUCT IS SPECIFICALLY CIRCLED.										
DIAGNOSIS (required):			ICD-1	LO CODE (	required):	Is patient receiving chemotherapy?  Yes  No				
🗌 Anemia in CKD, non-dialysis										
(If patient is on dialysis, different form must be used.)						Allergies/reactions:				
☐ Other:										
ORDERS:										
Epoetin-Alfa-epbx (Retacrit): units subcutaneously       Current Weight: kg										
🗌 weekly 🗋 every other week 📋 every 3 weeks 📄 monthly Refill until:										
DOSE					Date		Date	Date	Date	
ADJUSTMENTS	Hemoglobin									
PER PHARMACY	New Dose									
	(round per pharmacy)									
LABS: Send lab results to:										
Baseline Labs       prior to initiating epoetin therapy:         ☑       Hemoglobin/hematocrit (hemoglobin must be less than 10 g/dL)         ☑       Iron, IBC, TSAT, ferritin										
Maintenance Labs/Monitoring (box must be checked below):										
Hemoglobin / hematocrit prior to each dose (see frequency selected under "Orders" section above)										
✓ Iron, IBC, TSAT, ferritin:										
Please check one box below to indicate the frequency:							thar			
□ Every 3 months JAN (please circle starting month): → APR			FEB	MAR	<u>OR</u> Other:					
			MAY	JUN SEPT						
during the scheduled month)			AUG NOV	DEC						
Check if iron replacement is desired (based on maintenance labs ordered above).										
					TSAT %		Iron Sucrose D	osing		
Iron Sucrose (Venofer) IV Dosing Protocol:					> 20%		NO IRON			
<ul> <li>Target serum ferritin at least 100 ng/mL, TSAT at least 2</li> <li>Hold Iron Sucrose dose if ferritin &gt; 700 ng/mL</li> </ul>				east 20%	18-20%	200 mg IV weekly x 2 doses				
					15 - 17%		200 mg IV weekly x 3 doses			
					< 14%	200 mg IV weekly x 4 doses				
<ul> <li>Epoetin-Alfa-epbx (Retacrit) Dosing Protocol (adjust epoetin therapy as follows):</li> <li>If hemoglobin is equal to or greater than 10.6 g/dL: <ul> <li>HOLD epoetin dose.</li> <li>Recheck hemoglobin/hematocrit at the next scheduled appointment.</li> <li>When hemoglobin is less than 10.6 g/dL, restart epoetin with a 25% dose reduction from the last dose administered.</li> <li>Indicate dose adjustment above.</li> </ul> </li> <li>If hemoglobin increases by greater than 1 g/dL in any 2-calendar week period: <ul> <li>Continue with epoetin dose with a 25% dose reduction from the last dose administered.</li> <li>Indicate dose adjustment above.</li> </ul> </li> </ul>										
<ul> <li>After any 4-calendar weeks of therapy, if hemoglobin remains less than 9.5 g/dL AND the hemoglobin has not increased by at least 1 g/dL from baseline AND TSAT &gt; 20 %:         <ul> <li>Increase dose by 25% (using the last dose administered).</li> <li>Inform ordering provider of the dose increase.</li> <li>Indicate dose adjustment.</li> </ul> </li> <li>THE PROVIDER'S FULL SIGNATURE, DATE &amp; TIME IS TO FOLLOW THE ORDER - ABBREVIATIONS FOR NAMES ARE NOT ACCEPTABLE.</li> </ul>										
PATIENT NAME					OVIDER PRINTED NAME					
				PRO	ROVIDER SIGNATURE			DA	TE	TIME